Such a preventive role is determined by its ability to reduce the expression of the RAS components (AGT, AT1R and AGT II) and modulate positively the expression of genes involved in NAFLD. This evidence concerns the gene AGTR1 and metabolic dysfunction-associated steatotic liver disease.